BioArctic (BIOA-B.ST)

Executive Summary

BioArctic AB is a Swedish biopharmaceutical company focused on neurodegenerative diseases, best known for its Alzheimer's drug lecanemab (Leqembi®), which it co-developed with Eisai. Lecanemab received accelerated approval in the US in 2023 and full approval in 2024, and its commercialization is driving significant revenue for BioArctic through royalties. The company’s proprietary BrainTransporter® platform and protein aggregate targeting technology underpin a pipeline that includes exidavnemab, a monoclonal antibody targeting alpha-synuclein for Parkinson's disease and multiple system atrophy (MSA). Exidavnemab is currently in a Phase 2 trial (NCT06671938) with expected completion in August 2026. With a market capitalization of approximately $27.9 billion, BioArctic is well-capitalized to advance its pipeline. The company’s success depends on continued lecanemab sales growth, potential label expansions, and clinical progress in Parkinson's/MSA. Near-term catalysts include periodic lecanemab sales updates from Eisai, regulatory decisions on lecanemab for broader indications, and interim or final data from the exidavnemab Phase 2 trial.

Upcoming Catalysts (preview)

• Q2 2026Lecanemab quarterly sales update and potential label expansion decision85% success
• Q3 2026Phase 2 exidavnemab top-line data readout for Parkinson's Disease60% success
• Q4 2026Regulatory update on lecanemab for early Alzheimer's in EU or other regions70% success